Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Moderna Flu Vaccine Reversal FDA Refused to Review It—Then Advisers Voted 9-0 Twice Four months after FDA refused to file Moderna’s application, its vaccine advisers unanimously supported its benefit-risk…
Trending News
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy…
Editorial picks
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Moderna Flu Vaccine Reversal FDA Refused to Review It—Then Advisers Voted 9-0 Twice Four months after FDA refused to…
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
Categories
Investments
business news
Entrepreneurship
Startups
June, 2026
Chokepoints & Catalysts — Vol. I, No. 1
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma—covering GSK’s Nuvalent acquisition, Replimune’s RP1, India’s CRO opportunity, API dependence, and Lilly’s Germany investment cut.
Around The World
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma Then the Door Reopened: A Regulatory Whiplash Case Study RP1 showed a roughly one-in-three response rate, durable activity, and…
Pharma News
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA &…
GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy
GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite…
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA &…